Cargando…
Effect of the imatinib treatment regimen on the postoperative prognosis of patients with high-risk gastrointestinal stromal tumors
Background: Surgical resection is the standard treatment for localized and potentially resectable gastrointestinal stromal tumors (GISTs), If the postoperative pathology diagnosis indicates that patients are at high risk of recurrence, they should be treated with imatinib. Even though the introducti...
Autores principales: | Li, Yan-Shu, Li, Wei, Zeng, Qing-Sheng, Fu, Wei-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590845/ https://www.ncbi.nlm.nih.gov/pubmed/31354302 http://dx.doi.org/10.2147/OTT.S198129 |
Ejemplares similares
-
Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event
por: Liu, HeLi, et al.
Publicado: (2011) -
Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome
por: Zhao, Wen-Yi, et al.
Publicado: (2014) -
Postoperative Adjuvant Imatinib Therapy-Associated Nomogram to Predict Overall Survival of Gastrointestinal Stromal Tumor
por: Liu, Xuechao, et al.
Publicado: (2022) -
Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor
por: Wang, Gang, et al.
Publicado: (2021) -
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)